Maze R, Kapur R, Kelley M R, Hansen W K, Oh S Y, Williams D A
Section of Pediatric Hematology/Oncology, Indiana University School of Medicine, Indianapolis 46202, USA.
J Immunol. 1997 Jan 15;158(2):1006-13.
Bone marrow toxicity is a dose-limiting side effect of chloroethylnitrosourea (CNU) chemotherapeutic alkylating agents. A major determinant of CNU cytotoxicity is the methylation of guanine at the O6-position and the subsequent formation of interstrand DNA cross-links. O6-Methylguanine DNA methyltransferase (MGMT) removes alkyl groups from the O6 position of guanine and has been shown to repair CNU-induced DNA damage. We have previously demonstrated that transplantation of murine bone marrow cells transduced with a recombinant retroviral vector expressing MGMT via the human phosphoglycerate kinase promoter (PGK-MGMT) protects animals in vivo from acute myelotoxicity associated with CNU treatment. In the present study, we examined the effects of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), a commonly used CNU, on long term recovery of the lymphoid compartment, including thymus reconstitution, peripheral T and B cell populations, and lymphocyte mitogen responses in mice reconstituted with PGK-MGMT-transduced hemopoietic cells. Mice transplanted with either mock-infected control or PGK-MGMT-transduced stem cells were treated with five weekly doses of BCNU. Analysis of the lymphoid compartment demonstrated significant damage 3 mo after the last BCNU dose in control animals. In contrast, the profound deficiency in CD4+CD8+ double-positive thymocytes and mature lymphocytes observed in control mice surviving BCNU treatment was completely reversed in mice transplanted with PGK-MGMT-transduced bone marrow and was associated with molecular evidence of in vivo selection of transduced cells in the lymphoid compartment. Thus, long term immunodeficiency following CNU therapy may be prevented by genetic modification of murine hemopoietic stem cells with MGMT, leading to significant improvement in post-transplant immune function.
骨髓毒性是氯乙基亚硝基脲(CNU)化疗烷化剂的剂量限制性副作用。CNU细胞毒性的一个主要决定因素是鸟嘌呤在O6位的甲基化以及随后链间DNA交联的形成。O6-甲基鸟嘌呤DNA甲基转移酶(MGMT)从鸟嘌呤的O6位去除烷基,并已被证明可修复CNU诱导的DNA损伤。我们之前已经证明,用通过人磷酸甘油酸激酶启动子(PGK-MGMT)表达MGMT的重组逆转录病毒载体转导的小鼠骨髓细胞移植,可在体内保护动物免受与CNU治疗相关的急性骨髓毒性。在本研究中,我们研究了常用的CNU 1,3-双(2-氯乙基)-1-亚硝基脲(BCNU)对用PGK-MGMT转导的造血细胞重建的小鼠淋巴区室长期恢复的影响,包括胸腺重建、外周T和B细胞群体以及淋巴细胞有丝分裂原反应。用模拟感染对照或PGK-MGMT转导的干细胞移植的小鼠接受了五周剂量的BCNU治疗。淋巴区室分析显示,在对照动物中,最后一次BCNU剂量后3个月有明显损伤。相比之下,在接受BCNU治疗存活的对照小鼠中观察到的CD4+CD8+双阳性胸腺细胞和成熟淋巴细胞的严重缺乏,在用PGK-MGMT转导的骨髓移植的小鼠中完全得到逆转,并且与淋巴区室中体内转导细胞选择的分子证据相关。因此,通过用MGMT对小鼠造血干细胞进行基因改造,可以预防CNU治疗后的长期免疫缺陷,从而显著改善移植后的免疫功能。